Said UZ, Saada HN, Abd-Alla MS, Elsayed ME and Amin AM: Hesperidin attenuates brain biochemical changes of irradiated rats. Int J Radiat Biol. 88:613–618. 2012. View Article : Google Scholar : PubMed/NCBI

Bodkin JA, Cohen BM, Salomon MS, Cannon SE, Zornberg GL and Cole JO: Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine. J Nerv Ment Dis. 184:295–301. 1996. View Article : Google Scholar

Dunleavy DL: Mood and sleep changes with monoamine-oxidase inhibitors. Proc R Soc Med. 66:9511973.PubMed/NCBI

Shabbir F, Patel A, Mattison C, Bose S, Krishnamohan R, Sweeney E, Sandhu S, Nel W, Rais A, Sandhu R, Ngu N and Sharma S: Effect of diet on serotonergic neurotransmission in depression. Neurochem Int. 62:324–329. 2013. View Article : Google Scholar : PubMed/NCBI

Merikangas KR and Merikangas JR: Combination monoamine oxidase inhibitor and beta-blocker treatment of migraine, with anxiety and depression. Biol Psychiatry. 38:603–610. 1995. View Article : Google Scholar : PubMed/NCBI

Samson JA, Gurrera RJ, Nisenson L and Schildkraut JJ: Platelet monoamine oxidase activity and deficit syndrome schizophrenia. Psychiatry Res. 56:25–31. 1995. View Article : Google Scholar : PubMed/NCBI

Lawson DC, Turic D, Langley K, Pay HM, Govan CF, Norton N, Hamshere ML, Owen MJ, O’Donovan MC and Thapar A: Association analysis of monoamine oxidase A and attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 116B:84–89. 2003. View Article : Google Scholar : PubMed/NCBI

Wargelius HL, Malmberg K, Larsson JO and Oreland L: Associations of MAOA-VNTR or 5HTT-LPR alleles with attention-deficit hyperactivity disorder symptoms are moderated by platelet monoamine oxidase B activity. Psychiatr Genet. 22:42–45. 2012. View Article : Google Scholar : PubMed/NCBI

Nedic G, Pivac N, Hercigonja DK, Jovancevic M, Curkovic KD and Muck-Seler D: Platelet monoamine oxidase activity in children with attention-deficit/hyperactivity disorder. Psychiatry Res. 175:252–255. 2010. View Article : Google Scholar : PubMed/NCBI

Marziniak M, Mössner R, Benninghoff J, Syagailo YV, Lesch KP and Sommer C: Association analysis of the functional monoamine oxidase A gene promotor polymorphism in migraine. J Neural Transm. 111:603–609. 2004. View Article : Google Scholar : PubMed/NCBI

Moreno ML, Villanúa MA and Esquifino AI: Serum prolactin and luteinizing hormone levels and the activities of hypothalamic monoamine oxidase A and B and phenylethanolamine-N-methyl transferase are changed during sexual maturation in male rats treated neonatally with melatonin. J Pineal Res. 13:167–1731. 1992. View Article : Google Scholar

Youdim MB, Fridkin M and Zheng H: Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson’s disease and other neurodegenerative diseases. J Neural Transm. 111:1455–1471. 2004.PubMed/NCBI

Huang L, Lu C, Sun Y, Mao F, Luo Z, Su T, Jiang H, Shan W and Li X: Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer’s disease. J Med Chem. 55:8483–8492. 2012.PubMed/NCBI

Zheng H, Fridkin M and Youdim MB: From antioxidant chelators to site-activated multi-target chelators targeting hypoxia inducing factor, beta-amyloid, acetylcholinesterase and monoamine oxidase A/B. Mini Rev Med Chem. 12:364–370. 2012. View Article : Google Scholar

Gal S, Abassi ZA and Youdim MB: Limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30. Neurotox Res. 18:143–150. 2010. View Article : Google Scholar : PubMed/NCBI

Youdim MB and Lavie L: Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson’s disease. Life Sci. 55:2077–2082. 1994.PubMed/NCBI

Youdim MB and Bakhle YS: Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness. Br J Pharmacol. 147(Suppl 1): S287–S296. 2006.

Naoi M, Maruyama W, Akao Y, Yi H and Yamaoka Y: Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection. J Neural Transm Suppl. 67–77. 2006. View Article : Google Scholar : PubMed/NCBI

Zheng H, Youdim MB and Fridkin M: Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer’s therapy. ACS Chem Biol. 5:603–610. 2010.

Cummings JL: Lewy body diseases with dementia: pathophysiology and treatment. Brain Cogn. 28:266–280. 1995. View Article : Google Scholar : PubMed/NCBI

Drozak J and Kozłowski M: Monoamine oxidase as a target for drug action. Postepy Hig Med Dosw (Online). 60:498–515. 2006.(In Polish).

Siddiqui A, Mallajosyula JK, Rane A and Andersen JK: Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: implications for early intervention on disease progression. Neurobiol Dis. 43:527–532. 2011. View Article : Google Scholar

Bielecka AM, Paul-Samojedny M and Obuchowicz E: Moclobemide exerts anti-inflammatory effect in lipopolysaccharide-activated primary mixed glial cell culture. Naunyn Schmiedebergs Arch Pharmacol. 382:409–417. 2010. View Article : Google Scholar : PubMed/NCBI

Merad-Boudia M, Nicole A, Santiard-Baron D, Saillé C and Ceballos-Picot I: Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson’s disease. Biochem Pharmacol. 56:645–655. 1998.PubMed/NCBI

Hüll M, Berger M and Heneka M: Disease-modifying therapies in Alzheimer’s disease: how far have we come? Drugs. 66:2075–2093. 2006.

Rodríguez S, Ito T, He XJ, Uchida K and Nakayama H: Resistance of the golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-neurotoxicity is not only related with low levels of cerebral monoamine oxidase-B. Exp Toxicol Pathol. 65:127–133. 2013.PubMed/NCBI

Konradi C, Riederer P, Jellinger K and Denney R: Cellular action of MAO inhibitors. J Neural Transm Suppl. 25:15–25. 1987.

Weinstock M, Luques L, Poltyrev T, Bejar C and Shoham S: Ladostigil prevents age-related glial activation and spatial memory deficits in rats. Neurobiol Aging. 32:1069–1078. 2011. View Article : Google Scholar : PubMed/NCBI

Spina MB and Cohen G: Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci USA. 86:1398–1400. 1989. View Article : Google Scholar : PubMed/NCBI

Farooqui T and Farooqui AA: Lipid-mediated oxidative stress and inflammation in the pathogenesis of Parkinson’s disease. Parkinsons Dis. 2011:2474672011.PubMed/NCBI

Loeffler DA, DeMaggio AJ, Juneau PL, Havaich MK and LeWitt PA: Effects of enhanced striatal dopamine turnover in vivo on glutathione oxidation. Clin Neuropharmacol. 17:370–379. 1994. View Article : Google Scholar : PubMed/NCBI

Tapia-González S, Giráldez-Pérez RM, Cuartero MI, Casarejos MJ, Mena MÁ, Wang XF and Sánchez-Capelo A: Dopamine and α-synuclein dysfunction in Smad3 null mice. Mol Neurodegener. 6:722011.

Oberpichler-Schwenk H: Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment. Med Monatsschr Pharm. 28:224–227. 2005.(In German).

Chen JJ and Wilkinson JR: The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge? J Clin Pharmacol. 52:620–628. 2012. View Article : Google Scholar : PubMed/NCBI

Oreland L and Gottfries CG: Brain and brain monoamine oxidase in aging and in dementia of Alzheimer’s type. Prog Neuropsychopharmacol Biol Psychiatry. 10:533–540. 1986.

Sherif F, Gottfries CG, Alafuzoff I and Oreland L: Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer’s disease. J Neural Transm Park Dis Dement Sect. 4:227–240. 1992.PubMed/NCBI

Sparks DL, Woeltz VM and Markesbery WR: Alterations in brain monoamine oxidase activity in aging, Alzheimer’s disease, and Pick’s disease. Arch Neurol. 48:718–721. 1991.

Gulyás B, Pavlova E, Kása P, Gulya K, Bakota L, Várszegi S, Keller E, Horváth MC, Nag S, Hermecz I, Magyar K and Halldin C: Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. Neurochem Int. 58:60–68. 2011.PubMed/NCBI

Hirvonen J, Kailajärvi M, Haltia T, Koskimies S, Någren K, Virsu P, Oikonen V, Sipilä H, Ruokoniemi P, Virtanen K, Scheinin M and Rinne JO: Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin Pharmacol Ther. 85:506–512. 2009.PubMed/NCBI

Jossan SS, Gillberg PG, Karlsson I, Gottfries CG and Oreland L: Visualization of brain monoamine oxidase B (MAO-B) in dementia of Alzheimer’s type by means of large cryosection autoradiography: a pilot study. J Neural Transm Suppl. 32:61–65. 1990.

Fischer P, Götz ME, Ellinger B, Streifler M, Riederer P and Danielczyk W: Platelet monoamine oxidase B activity and vitamin B12 in dementia. Biol Psychiatry. 35:772–774. 1994. View Article : Google Scholar : PubMed/NCBI

Muck-Seler D, Presecki P, Mimica N, Mustapic M, Pivac N, Babic A, Nedic G and Folnegovic-Smalc V: Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 33:1226–1231. 2009.PubMed/NCBI

Riederer P and Jellinger K: Morphological and biochemical changes in the aging brain: pathophysiological and possible therapeutic consequences. Exp Brain Res. (Suppl 5): 158–166. 1982. View Article : Google Scholar : PubMed/NCBI

Battistin L, Rigo A, Bracco F, Dam M and Pizzolato G: Metabolic aspects of aging brain and related disorders. Gerontology. 33:253–258. 1987. View Article : Google Scholar : PubMed/NCBI

Mimica N, Mück-Seler D, Pivac N, Mustapić M, Dezeljin M, Stipcević T, Presecki P, Radonić E and Folnegović-Smalc V: Platelet serotonin and monoamine oxidase in Alzheimer’s disease with psychotic features. Coll Antropol. 32(Suppl 1): 119–122. 2008.

Götz ME, Fischer P, Gsell W, Riederer P, Streifler M, Simanyi M, Müller F and Danielczyk W: Platelet monoamine oxidase B activity in dementia. A 4-year follow-up. Dement Geriatr Cogn Disord. 9:74–77. 1998.PubMed/NCBI

Parnetti L, Reboldi GP, Santucci C, Santucci A, Gaiti A, Brunetti M, Cecchetti R and Senin U: Platelet MAO-B activity as a marker of behavioural characteristics in dementia disorders. Aging (Milano). 6:201–207. 1994.PubMed/NCBI

Bonuccelli U, Piccini P, Marazziti D, Cassano GB and Muratorio A: Increased platelet 3H-imipramine binding and monoamine oxidase B activity in Alzheimer’s disease. J Neural Transm Park Dis Dement Sect. 2:139–147. 1990.

Kennedy BP, Ziegler MG, Alford M, Hansen LA, Thal LJ and Masliah E: Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer’s disease. J Neural Transm. 110:789–801. 2003.PubMed/NCBI

Delumeau JC, Bentué-Ferrer D, Gandon JM, Amrein R, Belliard S and Allain H: Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases. J Neural Transm Suppl. 41:259–266. 1994.PubMed/NCBI

Grailhe R, Cardona A, Even N, Seif I, Changeux JP and Cloëz-Tayarani I: Regional changes in the cholinergic system in mice lacking monoamine oxidase A. Brain Res Bull. 78:283–289. 2009. View Article : Google Scholar : PubMed/NCBI

Riederer P, Danielczyk W and Grünblatt E: Monoamine oxidase-B inhibition in Alzheimer’s disease. Neurotoxicology. 25:271–277. 2004.

Thomas T: Monoamine oxidase-B inhibitors in the treatment of Alzheimer’s disease. Neurobiol Aging. 21:343–348. 2000.

Soto J, Ulibarri I, Jauregui JV, Ballesteros J and Meana JJ: Dissociation between I2-imidazoline receptors and MAO-B activity in platelets of patients with Alzheimer’s type dementia. J Psychiatr Res. 33:251–257. 1999.PubMed/NCBI

Finali G, Piccirilli M, Oliani C and Piccinin GL: L-deprenyl therapy improves verbal memory in amnesic Alzheimer patients. Clin Neuropharmacol. 14:523–536. 1991. View Article : Google Scholar : PubMed/NCBI

Weinreb O, Mandel S, Bar-Am O and Amit T: Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer’s disease: a tribute to Moussa Youdim. J Neural Transm. 118:479–492. 2011.PubMed/NCBI

Guay DR: Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson’s disease. Am J Geriatr Pharmacother. 4:330–346. 2006.

Grünblatt E, Schlösser R, Fischer P, Fischer MO, Li J, Koutsilieri E, Wichart I, Sterba N, Rujescu D, Möller HJ, Adamcyk W, Dittrich B, Müller F, Oberegger K, Gatterer G, Jellinger KJ, Mostafaie N, Jungwirth S, Huber K, Tragl KH, Danielczyk W and Riederer P: Oxidative stress related markers in the ‘VITA’ and the centenarian projects. Neurobiol Aging. 26:429–438. 2005.

Wu RM, Mohanakumar KP, Murphy DL and Chiueh CC: Antioxidant mechanism and protection of nigral neurons against MPP⁺ toxicity by deprenyl (selegiline). Ann NY Acad Sci. 738:214–221. 1994.PubMed/NCBI

Youdim MB, Amit T, Bar-Am O, Weinreb O and Yogev-Falach M: Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil. Neurotox Res. 10:181–192. 2006. View Article : Google Scholar

Bar-Am O, Amit T, Weinreb O, Youdim MB and Mandel S: Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation. J Alzheimers Dis. 21:361–371. 2010.PubMed/NCBI

Weinreb O, Mandel S, Bar-Am O, Yogev-Falach M, Avramovich-Tirosh Y, Amit T and Youdim MB: Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer’s disease drugs. Neurotherapeutics. 6:163–174. 2009.PubMed/NCBI

Weinstock M and Groner E: Rational design of a drug for Alzheimer’s disease with cholinesterase inhibitory and neuroprotective activity. Chem Biol Interact. 175:216–221. 2008.

Youdim MB, Fridkin M and Zheng H: Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech Ageing Dev. 126:317–326. 2005. View Article : Google Scholar : PubMed/NCBI

Adolfsson R, Gottfries CG, Oreland L, Wiberg A and Winblad B: Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci. 27:1029–1034. 1980. View Article : Google Scholar : PubMed/NCBI

Bongioanni P, Gemignani F, Boccardi B, Borgna M and Rossi B: Platelet monoamine oxidase molecular activity in demented patients. Ital J Neurol Sci. 18:151–156. 1997. View Article : Google Scholar : PubMed/NCBI

Ahlskog JE, Uitti RJ, Tyce GM, O’Brien JF, Petersen RC and Kokmen E: Plasma catechols and monoamine oxidase metabolites in untreated Parkinson’s and Alzheimer’s diseases. J Neurol Sci. 136:162–168. 1996.PubMed/NCBI

Konings CH, Scheltens P, Kuiper MA and Wolters EC: No evidence for abnormalities in kinetics of platelet monoamine oxidase in Alzheimer’s disease. Clin Chim Acta. 240:99–102. 1995.PubMed/NCBI

Winblad B, Gottfries CG, Oreland L and Wiberg A: Monoamine oxidase in platelets and brains of non-psychiatric and non-neurological geriatric patients. Med Biol. 57:129–132. 1979.PubMed/NCBI

Mann JJ, Stanley M, Neophytides A, de Leon MJ, Ferris SH and Gershon S: Central amine metabolism in Alzheimer’s disease: in vivo relationship to cognitive deficit. Neurobiol Aging. 2:57–60. 1981.

da Silva VB, de Andrade P, Kawano DF, Morais PA, de Almeida JR, Carvalho I, Taft CA and da Silva CH: In silico design and search for acetylcholinesterase inhibitors in Alzheimer’s disease with a suitable pharmacokinetic profile and low toxicity. Future Med Chem. 3:947–960. 2011.

Schneider LS, Severson JA, Chui HC, Pollock VE, Sloane RB and Fredrickson ER: Platelet tritiated imipramine binding and MAO activity in Alzheimer’s disease patients with agitation and delusions. Psychiatry Res. 25:311–322. 1988.PubMed/NCBI

Rodríguez MJ, Saura J, Billett EE, Finch CC and Mahy N: Cellular localization of monoamine oxidase A and B in human tissues outside of the central nervous system. Cell Tissue Res. 304:215–220. 2001.PubMed/NCBI

Sivasubramaniam SD, Finch CC, Rodriguez MJ, Mahy N and Billett EE: A comparative study of the expression of monoamine oxidase-A and -B mRNA and protein in non-CNS human tissues. Cell Tissue Res. 313:291–300. 2003. View Article : Google Scholar : PubMed/NCBI

Palmer AM and DeKosky ST: Monoamine neurons in aging and Alzheimer’s disease. J Neural Transm Gen Sect. 91:135–159. 1993.

Reinikainen KJ, Paljärvi L, Halonen T, Malminen O, Kosma VM, Laakso M and Riekkinen PJ: Dopaminergic system and monoamine oxidase-B activity in Alzheimer’s disease. Neurobiol Aging. 9:245–252. 1988.

Emilsson L, Saetre P, Balciuniene J, Castensson A, Cairns N and Jazin EE: Increased monoamine oxidase messenger RNA expression levels in frontal cortex of Alzheimer’s disease patients. Neurosci Lett. 326:56–60. 2002.PubMed/NCBI

Burke WJ, Li SW, Schmitt CA, Xia P, Chung HD and Gillespie KN: Accumulation of 3,4-dihydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer’s disease: mechanism of neuron death. Brain Res. 816:633–637. 1999.PubMed/NCBI

Chan-Palay V, Höchli M, Savaskan E and Hungerecker G: Calbindin D-28k and monoamine oxidase A immunoreactive neurons in the nucleus basalis of Meynert in senile dementia of the Alzheimer type and Parkinson’s disease. Dementia. 4:1–15. 1993.PubMed/NCBI

Barnett JH, Xu K, Heron J, Goldman D and Jones PB: Cognitive effects of genetic variation in monoamine neurotransmitter systems: a population-based study of COMT, MAOA, and 5HTTLPR. Am J Med Genet B Neuropsychiatr Genet. 156:158–167. 2011. View Article : Google Scholar : PubMed/NCBI

Klinteberg B, Levander SE, Oreland L, Asberg M and Schalling D: Neuropsychological correlates of platelet monoamine oxidase (MAO) activity in female and male subjects. Biol Psychol. 24:237–252. 1987. View Article : Google Scholar : PubMed/NCBI

Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, Welkowitz LA, Juster HR, Campeas R, Bruch MA, Cloitre M, Fallon B and Klein DF: Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry. 55:1133–1141. 1998. View Article : Google Scholar : PubMed/NCBI

Goldstein DM and Goldberg RL: Monoamine oxidase inhibitor-induced speech blockage. J Clin Psychiatry. 47:6041986.PubMed/NCBI

Delcker A and Gaertner HJ: Tolerability and antidepressive effect of brofaromine, a short-acting reversible MAO inhibitor - an open study. Eur Neuropsychopharmacol. 1:177–180. 1991. View Article : Google Scholar : PubMed/NCBI

Danilova RA, Moskvityna TA, Obukhova MF, Belopolskaya MV and Ashmarin IP: Pargyline conjugate-induced long-term activation of monoamine oxidase as an immunological model for depression. Neurochem Res. 24:1147–1151. 1999. View Article : Google Scholar : PubMed/NCBI

Giacobini G, Marchisio PC, Giacobini E and Koslow SH: Developmental changes of cholinesterases and monoamine oxidase in chick embryo spinal and sympathetic ganglia. J Neurochem. 17:1177–1185. 1970. View Article : Google Scholar : PubMed/NCBI

Van der Schyf CJ, Gal S, Geldenhuys WJ and Youdim MB: Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert Opin Investig Drugs. 15:873–886. 2006.

Ikemoto K, Kitahama K, Maeda T, Jouvet M and Nagatsu I: Cholinergic neurons with monoamine oxidase type B (MAOB)-activity in the laterodorsal tegmental nucleus of the mouse. Neurosci Lett. 271:53–56. 1999. View Article : Google Scholar : PubMed/NCBI

Nakamura S, Akiguchi I and Kimura J: A subpopulation of mouse striatal cholinergic neurons show monoamine oxidase activity. Neurosci Lett. 161:141–144. 1993. View Article : Google Scholar : PubMed/NCBI

Panagiotidis G, Stenström A and Lundquist I: Effects of adrenergic and cholinergic stimulation on islet monoamine oxidase activity and insulin secretion in the mouse. Eur J Pharmacol. 233:285–290. 1993. View Article : Google Scholar : PubMed/NCBI

Pintar JE, Breakefield XO and Patterson PH: Differences in monoamine oxidase activity between cultured noradrenergic and cholinergic sympathetic neurons. Dev Biol. 120:305–308. 1987. View Article : Google Scholar : PubMed/NCBI

Garrick NA and Murphy DL: Monoamine oxidase type A: differences in selectivity towards l-norepinephrine compared to serotonin. Biochem Pharmacol. 31:4061–4066. 1982. View Article : Google Scholar : PubMed/NCBI

Spector S: Monoamine oxidase in control of brain serotonin and norepinephrine content. Ann NY Acad Sci. 107:856–864. 1963. View Article : Google Scholar : PubMed/NCBI

Kumagae Y, Matsui Y and Iwata N: Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359. Jpn J Pharmacol. 55:121–128. 1991. View Article : Google Scholar : PubMed/NCBI

Baron M, Perumal AS, Levitt M and Cannova G: Platelet monoamine oxidase in schizophrenia with beta-phenylethylamine and benzylamine as substrates. Biol Psychiatry. 17:479–483. 1982.PubMed/NCBI

Lewinsohn R, Glover V and Sandler M: Beta-phenylethylamine and benzylamine as substrates for human monoamine oxidase A: A source of some anomalies? Biochem Pharmacol. 29:777–781. 1980.PubMed/NCBI

Moret C and Briley M: The importance of norepinephrine in depression. Neuropsychiatr Dis Treat. 7(Suppl 1): 9–13. 2011.PubMed/NCBI

Levitan MN, Chagas MH, Crippa JA, Manfro GG, Hetem LA, Andrada NC, Salum GA, Isolan L, Ferrari MC and Nardi AE; Brazilian Medical Association. Guidelines of the Brazilian Medical Association for the treatment of social anxiety disorder. Rev Bras Psiquiatr. 33:292–302. 2011.(In Portugese).

Schneier FR: Pharmacotherapy of social anxiety disorder. Expert Opin Pharmacother. 12:615–625. 2011. View Article : Google Scholar : PubMed/NCBI

Engelborghs S and De Deyn PP: The neurochemistry of Alzheimer’s disease. Acta Neurol Belg. 97:67–84. 1997.

Ishrat T, Parveen K, Khan MM, Khuwaja G, Khan MB, Yousuf S, Ahmad A, Shrivastav P and Islam F: Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer’s type. Brain Res. 1281:117–127. 2009.PubMed/NCBI

Schaeffer EL and Gattaz WF: Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. Psychopharmacology (Berl). 198:1–27. 2008. View Article : Google Scholar

Tran MH, Yamada K and Nabeshima T: Amyloid beta-peptide induces cholinergic dysfunction and cognitive deficits: a minireview. Peptides. 23:1271–1283. 2002. View Article : Google Scholar : PubMed/NCBI

Dhull DK, Jindal A, Dhull RK, Aggarwal S, Bhateja D and Padi SS: Neuroprotective effect of cyclooxygenase inhibitors in ICV-STZ induced sporadic Alzheimer’s disease in rats. J Mol Neurosci. 46:223–235. 2012.PubMed/NCBI

McNaull BB, Todd S, McGuinness B and Passmore AP: Inflammation and anti-inflammatory strategies for Alzheimer’s disease - a mini-review. Gerontology. 56:3–14. 2010.

Cai ZY, Yan Y and Chen R: Minocycline reduces astrocytic reactivation and neuroinflammation in the hippocampus of a vascular cognitive impairment rat model. Neurosci Bull. 26:28–36. 2010. View Article : Google Scholar : PubMed/NCBI

Agostinho P, Cunha RA and Oliveira C: Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer’s disease. Curr Pharm Des. 16:2766–2778. 2010.

Hardy J and Selkoe DJ: The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 297:353–356. 2002.

Song W, Zhou LJ, Zheng SX and Zhu XZ: Amyloid-beta 25–35 peptide induces expression of monoamine oxidase B in cultured rat astrocytes. Acta Pharmacol Sin. 21:557–563. 2000.

Carter SF, Schöll M, Almkvist O, Wall A, Engler H, Långström B and Nordberg A: Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med. 53:37–46. 2012. View Article : Google Scholar : PubMed/NCBI

Hu MK, Liao YF, Chen JF, Wang BJ, Tung YT, Lin HC and Lee KP: New 1,2,3,4-tetrahydroisoquinoline derivatives as modulators of proteolytic cleavage of amyloid precursor proteins. Bioorg Med Chem. 16:1957–1965. 2008. View Article : Google Scholar : PubMed/NCBI

Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin M and Youdim MB: Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer’s disease. J Neurochem. 100:490–502. 2007.PubMed/NCBI

Ono K, Hasegawa K, Naiki H and Yamada M: Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer’s beta-amyloid fibrils in vitro. Neurochem Int. 48:275–285. 2006.PubMed/NCBI

Yogev-Falach M, Bar-Am O, Amit T, Weinreb O and Youdim MB: A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J. 20:2177–2179. 2006. View Article : Google Scholar : PubMed/NCBI

Weinreb O, Amit T, Bar-Am O, Sagi Y, Mandel S and Youdim MB: Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. J Neural Transm Suppl. 457–465. 2006. View Article : Google Scholar : PubMed/NCBI

Zhiyou C, Yong Y, Shanquan S, Jun Z, Liangguo H, Ling Y and Jieying L: Upregulation of BACE1 and beta-amyloid protein mediated by chronic cerebral hypoperfusion contributes to cognitive impairment and pathogenesis of Alzheimer’s disease. Neurochem Res. 34:1226–1235. 2009.PubMed/NCBI

Liu H, Li Z, Qiu D, Gu Q, Lei Q and Mao L: The inhibitory effects of different curcuminoids on β-amyloid protein, β-amyloid precursor protein and β-site amyloid precursor protein cleaving enzyme 1 in swAPP HEK293 cells. Neurosci Lett. 485:83–88. 2010.

Yogev-Falach M, Amit T, Bar-Am O, Weinstock M and Youdim MB: Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J. 16:1674–1676. 2002.PubMed/NCBI

Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M and Amit T: Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res. 79:172–179. 2005. View Article : Google Scholar : PubMed/NCBI

Youdim MB, Amit T, Bar-Am O, Weinstock M and Yogev-Falach M: Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326. Ann NY Acad Sci. 993:378–393. 2003. View Article : Google Scholar : PubMed/NCBI

Kupershmidt L, Amit T, Bar-Am O, Youdim MB and Weinreb O: The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer’s disease. Antioxid Redox Signal. 17:860–877. 2012.PubMed/NCBI

Yang HQ, Sun ZK, Ba MW, Xu J and Xing Y: Involvement of protein trafficking in deprenyl-induced alpha-secretase activity regulation in PC12 cells. Eur J Pharmacol. 610:37–41. 2009. View Article : Google Scholar : PubMed/NCBI

Tsunekawa H, Noda Y, Mouri A, Yoneda F and Nabeshima T: Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25–35). Behav Brain Res. 190:224–232. 2008.PubMed/NCBI

Calderón-Garcidueñas L, Kavanaugh M, Block M, D’Angiulli A, Delgado-Chávez R, Torres-Jardón R, González-Maciel A, Reynoso-Robles R, Osnaya N, Villarreal-Calderon R, Guo R, Hua Z, Zhu H, Perry G and Diaz P: Neuroinflammation, hyperphosphorylated tau, diffuse amyloid plaques, and down-regulation of the cellular prion protein in air pollution exposed children and young adults. J Alzheimers Dis. 28:93–107. 2012.

Stozicka Z, Zilka N, Novak P, Kovacech B, Bugos O and Novak M: Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer’s disease. J Neuroinflammation. 7:642010.

McGeer EG and McGeer PL: Neuroinflammation in Alzheimer’s disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis. 19:355–361. 2010.

Hensley K: Neuroinflammation in Alzheimer’s disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J Alzheimers Dis. 21:1–14. 2010.

Streit WJ: Microglial activation and neuroinflammation in Alzheimer’s disease: a critical examination of recent history. Front Aging Neurosci. 2:222010.

Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, Löffler J and Richards JG: Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience. 62:15–30. 1994. View Article : Google Scholar

Menazza S, Blaauw B, Tiepolo T, Toniolo L, Braghetta P, Spolaore B, Reggiani C, Di Lisa F, Bonaldo P and Canton M: Oxidative stress by monoamine oxidases is causally involved in myofiber damage in muscular dystrophy. Hum Mol Genet. 19:4207–4215. 2010. View Article : Google Scholar : PubMed/NCBI

Zheng H, Amit T, Bar-Am O, Fridkin M, Youdim MB and Mandel SA: From anti-Parkinson’s drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer’s disease. J Alzheimers Dis. 30:1–16. 2012.

Dimpfel W and Hoffmann JA: Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro. BMC Pharmacol. 11:22011. View Article : Google Scholar : PubMed/NCBI

Youdim MB, Maruyama W and Naoi M: Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today (Barc). 41:369–391. 2005. View Article : Google Scholar : PubMed/NCBI

Weinreb O, Amit T, Bar-Am O and Youdim MB: Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer’s disease treatment. Curr Drug Targets. 13:483–494. 2012.

Weinreb O, Amit T, Bar-Am O and Youdim MB: A novel anti-Alzheimer’s disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor. Int Rev Neurobiol. 100:191–215. 2011.

Alafuzoff I, Helisalmi S, Heinonen EH, Reinikainen K, Hallikainen M, Soininen H and Koivisto K: Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer’s disease. Eur J Clin Pharmacol. 55:815–819. 2000.PubMed/NCBI

Birks J and Flicker L: Selegiline for Alzheimer’s disease. Cochrane Database Syst Rev. CD0004422003.

Wilcock GK, Birks J, Whitehead A and Evans SJ: The effect of selegiline in the treatment of people with Alzheimer’s disease: a meta-analysis of published trials. Int J Geriatr Psychiatry. 17:175–183. 2002.

Birks J and Flicker L: Selegiline for Alzheimer’s disease. Cochrane Database Syst Rev. CD0004422000.

Filip V and Kolibás E: Selegiline in the treatment of Alzheimer’s disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. J Psychiatry Neurosci. 24:234–243. 1999.

Lawlor BA, Aisen PS, Green C, Fine E and Schmeïdler J: Selegiline in the treatment of behavioural disturbance in Alzheimer’s disease. Int J Geriatr Psychiatry. 12:319–322. 1997.

Sano M, Ernesto C, Klauber MR, Schafer K, Woodbury P, Thomas R, Grundman M, Growdon J and Thal LJ: Rationale and design of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 10:132–140. 1996. View Article : Google Scholar : PubMed/NCBI

Schneider LS, Olin JT and Pawluczyk S: A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer’s disease. Am J Psychiatry. 150:321–323. 1993.PubMed/NCBI

Youdim MB: The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Curr Alzheimer Res. 3:541–550. 2006. View Article : Google Scholar : PubMed/NCBI

Zheng H, Fridkin M and Youdim MB: Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer’s disease. Neurochem Res. 35:2117–2123. 2010.PubMed/NCBI

Zheng H, Weiner LM, Bar-Am O, Epsztejn S, Cabantchik ZI, Warshawsky A, Youdim MB and Fridkin M: Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. Bioorg Med Chem. 13:773–783. 2005.PubMed/NCBI

Gökhan-Kelekçi N, Yabanoǧlu S, Küpeli E, Salgin U, Ozgen O, Uçar G, Yešilada E, Kendi E, Yešilada A and Bilgin AA: A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics. Bioorg Med Chem. 15:5775–5786. 2007.PubMed/NCBI

Yamada M and Yasuhara H: Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology. 25:215–221. 2004. View Article : Google Scholar : PubMed/NCBI

Yu PH: Pharmacological and clinical implications of MAO-B inhibitors. Gen Pharmacol. 25:1527–1539. 1994. View Article : Google Scholar : PubMed/NCBI